United Therapeutics (NASDAQ:UTHR) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says

United Therapeutics (NASDAQ:UTHR) had its price target upped by analysts at Wells Fargo & Company from $486.00 to $575.00 in a note issued to investors on Tuesday,Benzinga reports. The firm currently has an “equal weight” rating on the biotechnology company’s stock. Wells Fargo & Company‘s price target suggests a potential upside of 0.83% from the company’s previous close.

A number of other analysts have also recently weighed in on UTHR. Weiss Ratings reaffirmed a “buy (b)” rating on shares of United Therapeutics in a research report on Monday, December 29th. Jefferies Financial Group reissued a “buy” rating on shares of United Therapeutics in a research report on Monday, March 2nd. HC Wainwright boosted their price objective on United Therapeutics from $525.00 to $600.00 and gave the stock a “buy” rating in a research note on Thursday, February 26th. Cantor Fitzgerald upped their target price on United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a research report on Thursday, March 12th. Finally, Bank of America increased their target price on United Therapeutics from $569.00 to $626.00 and gave the company a “neutral” rating in a research note on Tuesday. Nine research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $586.00.

United Therapeutics Stock Performance

NASDAQ UTHR opened at $570.27 on Tuesday. The firm has a market capitalization of $24.99 billion, a price-to-earnings ratio of 20.44, a PEG ratio of 1.72 and a beta of 0.75. United Therapeutics has a one year low of $266.98 and a one year high of $607.89. The company’s 50 day moving average price is $502.93 and its 200 day moving average price is $476.94.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.78 by $0.92. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The company had revenue of $790.20 million during the quarter, compared to the consensus estimate of $814.80 million. During the same period in the previous year, the firm earned $6.19 earnings per share. United Therapeutics’s revenue for the quarter was up 7.4% on a year-over-year basis. Sell-side analysts forecast that United Therapeutics will post 24.48 EPS for the current fiscal year.

Insider Activity at United Therapeutics

In other United Therapeutics news, CEO Martine A. Rothblatt sold 9,500 shares of the company’s stock in a transaction dated Thursday, March 26th. The shares were sold at an average price of $535.81, for a total value of $5,090,195.00. Following the completion of the transaction, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at $21,707,270.53. This represents a 19.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Paul A. Mahon sold 8,300 shares of the firm’s stock in a transaction dated Thursday, March 19th. The shares were sold at an average price of $529.95, for a total value of $4,398,585.00. Following the sale, the executive vice president owned 45,172 shares of the company’s stock, valued at $23,938,901.40. This represents a 15.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 333,820 shares of company stock valued at $165,495,478. Corporate insiders own 10.30% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Rockefeller Capital Management L.P. increased its holdings in United Therapeutics by 10.6% during the 4th quarter. Rockefeller Capital Management L.P. now owns 1,323 shares of the biotechnology company’s stock worth $645,000 after purchasing an additional 127 shares during the last quarter. Corient Private Wealth LLC boosted its stake in shares of United Therapeutics by 13.5% during the 4th quarter. Corient Private Wealth LLC now owns 19,248 shares of the biotechnology company’s stock valued at $9,379,000 after buying an additional 2,289 shares during the last quarter. Rehmann Capital Advisory Group boosted its stake in shares of United Therapeutics by 9.8% during the 4th quarter. Rehmann Capital Advisory Group now owns 3,619 shares of the biotechnology company’s stock valued at $1,767,000 after buying an additional 324 shares during the last quarter. Tobam grew its position in shares of United Therapeutics by 28.9% during the fourth quarter. Tobam now owns 9,857 shares of the biotechnology company’s stock worth $4,803,000 after buying an additional 2,211 shares in the last quarter. Finally, Wick Capital Partners LLC acquired a new stake in shares of United Therapeutics during the fourth quarter worth approximately $297,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

More United Therapeutics News

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Phase 3 TETON‑1 results: Tyvaso met the trial’s key endpoint in idiopathic pulmonary fibrosis (IPF), driving a sharp runup in the stock because success expands Tyvaso’s addressable market beyond pulmonary arterial hypertension. United Therapeutics (UTHR) Is Up 11.5% After Positive IPF Phase 3 Tyvaso Data Met Key Endpoint
• Positive Sentiment: Company press release and institutional coverage reinforced the data readout, giving investors more confidence in a potential FDA filing and commercial upside for Tyvaso in IPF. United Therapeutics reports positive results for lung drug
• Positive Sentiment: Multiple analyst upgrades and price‑target increases (Bank of America, Wells Fargo, HC Wainwright, others) followed the TETON‑1 readout, amplifying buying pressure and pre‑market gaps. Higher targets highlight expected revenue expansion if IPF approval/commercialization succeeds. United Therapeutics Gets Dual Target Hikes From BofA and Wells Fargo
• Positive Sentiment: Sell‑side momentum: some firms (e.g., HC Wainwright) moved to Buy and raised targets materially, which supports further upside if clinical and regulatory paths stay on track. HC Wainwright raises UTHR price target to $660
• Neutral Sentiment: Valuation check: analysts and market write‑ups are reassessing UTHR’s valuation after the IPF data — positive clinical news boosts forward revenue expectations but raises near‑term valuation scrutiny. Investors should weigh upside against higher multiples. Assessing United Therapeutics (UTHR) Valuation After Positive Tyvaso Phase 3 IPF Trial Results
• Neutral Sentiment: Options flow and momentum trading: unusually high options activity and gap‑up headlines indicate speculative positioning that can amplify moves and volatility around catalysts (e.g., filings, guidance). United Therapeutics Target of Unusually High Options Trading (NASDAQ:UTHR)
• Neutral Sentiment: Sell‑side balance: some firms raised targets but left neutral/equal‑weight ratings, reflecting disagreement on upside vs. execution risk; that keeps upside concentrated in execution and regulatory milestones. Analysts Are Neutral on Top Healthcare Stocks: Gilead Sciences (GILD), United Therapeutics (UTHR)
• Negative Sentiment: Near‑term caution: some commentary flags valuation and execution risk plus mixed earnings‑estimate revision trends — these could limit further near‑term gains unless management provides clear regulatory/launch guidance. United Therapeutics (UTHR) Moves 12.5% Higher: Will This Strength Last?

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.